Feline tumor immunotherapy is a treatment that strengthens the immune system to recognize and attack cancer cells. Effective management and selection criteria are important.





| Item | Key Points |
|---|---|
| Who Directs Treatment | Consult the veterinarian/oncologist who diagnosed the tumor, rather than choosing an advertised product |
| Treatment Position | First plan whether it will be used alongside standard treatments such as surgery, chemotherapy, and radiation |
| Supplement Caution | Be wary of supplements with unproven efficacy and exaggerated advertising; check with your veterinarian before administering |
| Observation Records | Record changes in appetite, weight, and vitality and share them at the exam |
This is not a table recommending specific products or hospitals, but a reference for when you consult your veterinarian. Always make treatment and testing decisions together with your veterinarian through an examination.
Precautions and Contraindications
Immunotherapy works by stimulating a cat’s immune response, so it should be used with caution in cats with autoimmune diseases. Additionally, because it may interact with other ongoing treatments or medications, always consult the veterinarian who diagnosed the tumor. If your cat shows loss of appetite, vomiting, or fatigue during treatment, do not attempt to manage these symptoms on your own; contact your veterinary clinic immediately for professional care.


A veterinarian who majored in veterinary medicine at Khon Kaen University, Thailand, and completed the IVSA program at North Carolina State University in the United States. Drawing on clinical experience at animal hospitals, he works in the pet healthcare field and is dedicated to building a digital care environment that connects pet parents with veterinarians.
Share
[1] Rassnick KM, Williams LE, Kristal O et al. (2008) Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005). Journal of the American Veterinary Medical Association 232, 1200-1205.
[2] Lee, W.S., Yang, H., Chon, H.J. and Kim, C. (2020) Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Experimental & Molecular Medicine 52(9), 1475–1485.
[3] Mitchell, L., Thamm, D.H. and Biller, B.J. (2012) Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. Journal of Veterinary Internal Medicine 26(2), 355–362.